Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2244 - Chronic pleural effusion in malignancy: a single center’s ten years expertise with indwelling pleural catheters

Date

10 Sep 2017

Session

Poster display session

Topics

Cancers in Adolescents and Young Adults (AYA);  End-of-life Care

Presenters

Nikolaj Frost

Citation

Annals of Oncology (2017) 28 (suppl_5): v497-v501. 10.1093/annonc/mdx382

Authors

N. Frost1, M. Brünger2, B. Temmesfeld-Wollbrück1, D. Schürmann1, N. Suttorp1

Author affiliations

  • 1 Department Of Infectious Diseases And Pneumonology, Charité Universitätsmedizin Berlin, 13353 - Berlin/DE
  • 2 Institute Of Medical Sociology And Rehabilitation Science, Charité Universitätsmedizin Berlin, 10115 - Berlin/DE
More

Resources

Abstract 2244

Background

Chronic and recurrent pleural effusion (PE) in malignant diseases is a common cause of dyspnea, cough and chest pain. The vast majority is malignant pleural effusion (MPE), nevertheless disease-associated but not directly disease-caused paramalignant pleural effusions (PPE) have also been described. Talc pleurodesis had been the only treatment option for decades, while for 20 years indwelling pleural catheters (IPC) have emerged as an alternative leading to spontaneous pleurodesis without any chemical agent in 40-50%.

Methods

Our aim is to explore patient characteristics, procedural variables and outcomes in a large population of patients with IPC due to PE in malignancy. Further, our objective is to identify factors associated with outcome.

Results

From 2006 until 2016 448 IPC were inserted in 395 patients, 52 received bilateral drainages (12.7%). 77.0% of the effusions were malignant (n = 304), 14.9% paramalignant (n = 59), in 8.1% the etiology could not be clarified (n = 32). The most common underlying diseases were ovarian cancer (30.6%, 121 patients), lung cancer (23.0%, 91 patients) and breast cancer (11.4%, 45 patients). The median length of insertion was 1.2 months (0.03-23.6), the median survival time after insertion 2.4 months (lung cancer 1.6 months, ovarian cancer 2.8 months, breast cancer 4.0 months). Spontaneous pleurodesis was observed in 28.6% (128/448 catheters) and was significantly associated with overall survival (HR 0.54, 95%-CI 0.39-0.75, p 

Conclusions

In conclusion, our retrospective series is the largest to date to report on IPC in malignancy and showed a manageable safety profile. Spontaneous pleurodesis was significantly associated with survival.

Clinical trial identification

Not applicable

Legal entity responsible for the study

Charité Universitätsmedizin Berlin

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.